ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4135-4140

  Hayes, Mose ^a   Lan, Cynthia ^b   Yan, Jingsheng ^c   Xie, Yang ^c   Gray, Toby ^d   Amirkhan, Robin H ^d   Dowell, Jonathan E ^c,d  

^a Sacred Heart Medical Oncology   (United States)

^b Department of Hematology/Oncology Central Valley ^*  (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d Veterans Affairs North Texas Health Care System   (United States)

Author keywords

Cisplatin; DNA repair; ERCC1 protein; Head and neck neoplasms; Radiation

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; HYPOPHARYNX CANCER; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; NASOPHARYNX CANCER; OROPHARYNX CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RADIOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84855185962     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer Statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Gossage L and Madhusudan S: Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33: 565-577, 2007. (Pubitemid 47355341)
3. Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14: 1291-1295, 2008. (Pubitemid 351413906)
4. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, LeChevalier T, and Soria JC: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006. (Pubitemid 44343542)
5. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC and Fouret P: Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 13: 3855-3859, 2007. (Pubitemid 47037591)
6. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH and Park K: ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99: 167-172, 2008. (Pubitemid 351920246)
7. Mehra R, Cai KQ, Zhu F, Weaver JE, Nicolaou N, Lango M, Ridge JA, Godwin AK and Burtness BA: ERCCI is a predictive biomarker of survival in squamous cell carcinoma of the head and neck [abstract]. Abstract no. 2804. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research 2010 April 17-21 Washington DC. Philadelphia (PA): AACR, 2010.
8. Saada E, Thariat J, Ettore F, Sudaka A, Chamorey E, Italiano A, Poissonet G, Bensadoun R, Dassonville O and Peyrade F: Correlation of global expression of ERCC1 in head and neck squamous cell carcinoma with prognosis [abstract]. J Clin Oncol 27(20 Suppl): e17016, 2009.
9. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Vinolas N, Paz-Ares L, Lopez-Vivanco G, Munoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D and Rosell R: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small cell lung cancer. J Clin Oncol 25: 2747-2754, 2007. (Pubitemid 47123183)
10. Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE 2nd, Danenberg PV and Harpole DH Jr.: High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11: 2215-2221, 2005.
11. Nix P, Greenman J, Stafford N and Cawkwell L: Expression of XRCC1 and ERCC1 proteins in radioresistant and radiosensitive laryngeal cancer. Cancer Ther 2: 47-53, 2004.